Álvaro H. Borges

Álvaro H. Borges

Auto-generated profile, based on publicly available information

Álvaro H. Borges

Department of Infectious Disease Immunology, Centre for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
ÁBÁlvaro H Borges
Álvaro H Borges
MRMarisa Russell
Marisa Russell
DTDereck Tait
Dereck Tait
TSThomas J Scriba
Thomas J Scriba
ENElisa Nemes
Elisa Nemes
PGPOR TB study group
POR TB study group

1 April 2024 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
DTDereck Tait
Dereck Tait
ADAndreas Diacon
Andreas Diacon
ÁBÁlvaro H Borges
Álvaro H Borges
EBElana van Brakel
Elana van Brakel
DHDavid Hokey
David Hokey
RDRodney Dawson
Rodney Dawson
Background: H56:IC31 is a candidate vaccine against tuberculosis (TB) with the potential to reduce TB recurrence rate. It is thus important for future clinical trials to demonstrate safety and immunogenicity of H56:IC31 in individuals treated for TB. Methods: Twenty-two adults confirmed to be Mycobacterium tuberculosis negative (by 2 GeneXpert tests or 2 sputum cultures) after 4–5 months of TB treatment, and not more than 28 days after completion of TB treatment, were randomized to receive 2 doses of H56:IC31 (5 mg H56:500 nmol IC31; n = 16) or placebo (n = 6) 56 days apart. Participants were followed for 420 days for safety and immunogenicity. Results: H56:IC31 vaccination was associated with an acceptable safety profile, consisting mostly of mild self-limited injection site reactions. No serious adverse events or vaccine-related severe adverse events were reported. H56:IC31 induced a CD4+ T-cell response for Ag85B and ESAT-6, with ESAT-6 being immunodominant, which persisted through 6 months after the last vaccination. There was some evidence of CD8+ T-cell responses for both Ag85B and ESAT-6, but to a lesser extent than CD4+ responses. Conclusions: H56:IC31 was associated with an acceptable safety profile, and induced a predominant CD4+ T-cell response, in adults recently treated for drug-susceptible, uncomplicated pulmonary TB. Clinical Trials Registration: NCT02375698.

28 January 2020 in APMIS
Verified
Journal Article
Open access
PDF file
MNMarinho Marques da Silva Neto
Marinho Marques da Silva Neto
CBCarlos Brites
Carlos Brites
ÁBÁlvaro H. Borges
Álvaro H. Borges
HIV+ persons have a significantly increased risk of cancer when compared to the general population. The excess cancer risk observed during HIV infection is particularly higher for infection‐related malignancies. Mechanisms underlying this remain unclear, but both HIV‐related and HIV‐unrelated factors have been postulated to play a role. Here, we (i) review newly published data on cancer burden in the setting of HIV infection with a focus on HIV‐related risk factors for cancer; (ii) discuss emerging data on cancer among HIV+ persons living in low‐ and middle‐income countries; and (iii) review guideline recommendations for cancer screening among HIV+ persons and discuss ongoing studies investigating strategies for cancer screening among HIV+ patients.

5 September 2022 in Expert Review of Vaccines
Verified
Journal Article
Closed access
ÁBÁlvaro H. Borges
Álvaro H. Borges
FFFrank Follmann
Frank Follmann
JDJes Dietrich
Jes Dietrich
Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen in the world. A licensed vaccine is not yet available, but the first vaccines have entered clinical trials.We descri...

29 December 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
DRDaniel Bräuner Rasmussen
Daniel Bräuner Rasmussen
DMDina Leth Møller
Dina Leth Møller
SHSebastian Rask Hamm
Sebastian Rask Hamm
ÁBÁlvaro H. Borges
Álvaro H. Borges
ANAlex Christian Yde Nielsen Nielsen
Alex Christian Yde Nielsen Nielsen
SNSusanne Dam Nielsen
Susanne Dam Nielsen
Infection with BK polyomavirus (BKPyV) is a common opportunistic infection after kidney transplantation (KT) and may affect graft function. We aimed to determine the incidence, risk factors, and clinical outcomes of BKPyV DNAemia in a prospective cohort of 601 KT recipients transplanted from 2012 to 2020. BKPyV PCR on plasma was performed at days 60, 90, 180, 270, and 360 post-KT. Any BKPyV DNAemia was defined as a single BKPyV DNA of ≥1000 copies/mL. Severe BKPyV DNAemia was defined as two consecutive BKPyV DNA of ≥10,000 copies/mL. Cumulative incidences were investigated using the Aalen–Johansen estimator, and the risk factors were investigated in Cox proportional hazard models. The incidence of any BKPyV DNAemia and severe BKPyV DNAemia was 21% (18–25) and 13% (10–16) at one year post-KT, respectively. Recipient age > 50 years (aHR, 1.72; 95% CI 1.00–2.94; p = 0.049), male sex (aHR, 1.96; 95% CI 1.17–3.29; p = 0.011), living donors (aHR, 1.65; 95% CI 1.03–2.74; p = 0.045), and >3 HLA-ABDR mismatches (aHR, 1.72; 95% CI 1.01–2.94; p = 0.046) increased the risk of severe BKPyV DNAemia. Any BKPyV DNAemia was associated with an increased risk of graft function decline (aHR, 2.26; 95% CI 1.00–5.12; p = 0.049), and severe BKPyV DNAemia was associated with an increased risk of graft loss (aHR, 3.18; 95% CI 1.06–9.58; p = 0.039). These findings highlight the importance of BKPyV monitoring post-KT.

1 December 2014 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
ÁBÁlvaro H Borges
Álvaro H Borges
ALAndreas Lundh
Andreas Lundh
TGThe Nordic Cochrane Group
The Nordic Cochrane Group
BTBritta Tendal
Britta Tendal
THTania B. Huedo-Medina
Tania B. Huedo-Medina
JLJens Lundgren
Jens Lundgren
Background: Results. from RCTs suggest that NNRTIs may cause faster virological suppression and PI/r may recover more CD4 cells. It is unknown if differences in immunological and virological endpoints are clinically relevant, as individual RCTs have not been powered to compare clinical outcomes.